SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-032552
Filing Date
2022-12-23
Accepted
2022-12-23 16:02:48
Documents
15
Period of Report
2022-12-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20221223.htm   iXBRL 8-K 47826
2 EX-1.1 exhibit11amendmentno2toope.htm EX-1.1 20910
3 EX-5.1 exhibit51opinionofcooley.htm EX-5.1 5635
7 GRAPHIC exhibit51opinionofcooley001.jpg GRAPHIC 361073
  Complete submission text file 0001628280-22-032552.txt   720319

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20221223.xsd EX-101.SCH 1941
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20221223_lab.xml EX-101.LAB 25133
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20221223_pre.xml EX-101.PRE 13080
9 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20221223_htm.xml XML 11309
Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 221485369
SIC: 2836 Biological Products, (No Diagnostic Substances)